Poul Sørensen
Chief Scientific Officer Allero Therapeutics
Poul Sørensen has extensive R&D and corporate development leadership from Pharmacia, LEO Pharma, Micromet, ALK and Stallergenes Greer, spanning immuno-oncology, inflammation, neurology, allergies and immune disorders. At ALK and Stallergenes Greer he led antigen-specific allergy immunotherapy research and corporate development, including the launch of the first AIT tablet in the US — experience he now applies as CSO and co-founder of Allero, translating those learnings into antigen-specific immunotherapies for autoimmune diseases. Beyond Allero, as a serial biotech entrepreneur, Poul has co-founded several start-ups. He holds a PhD in Biochemistry from the University of Copenhagen and is Honorary Professor in Biomedicine at Aarhus University.
Seminars
- Allero’s SOMIT platform translates learnings from Allergen Immunotherapy (AIT) to address requirements for next-generation antigen-specific immunotherapies in other immune-mediated disorders, including safety, efficacy, scalability, and patientfriendliness
- SOMIT is a non-invasive, scalable oral patch-based, first-in-class approach that leverages the tolerance gateway of the oral mucosa
- SOMIT has platform potential across a wide range of immune-mediated disorders where the triggering antigen is known e.g., allergies, autoimmune diseases, and anti-drug antibodies (ADA), with new developments underway on an mRNA-based approach
